This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.2 | Special Copayment Reduction: V117 |
| B. Synonyms | Argininemia, ARG1 deficiency, Hyperargininemia, Arginase deficiency |
| C. Adult onset | Likelihood of first diagnosis in adulthood: not low — because severe neonatal encephalopathy is rare in argininemia, many cases in the era before newborn screening were first diagnosed in childhood to adolescence. In patients with mild to moderate residual activity, it may present as progressive spastic paraplegia as late as adulthood. Early diagnosis has increased since its inclusion in newborn screening. |
| 1. History | 1969, Terheggen et al. first described patients with hyperargininemia and spastic paraplegia → cloning of the ARG1 gene → establishment of diagnosis by measurement of erythrocyte ARG1 activity → tandem MS/MS newborn screening (elevated arginine as marker) → clinical introduction of liver transplantation. |
| 2. Causes | Pathogenic variants in the ARG1 gene (6q23.2) → arginase 1 deficiency → blocked conversion of arginine to urea + ornithine → arginine accumulation (hyperargininemia) + mild hyperammonemia. Autosomal recessive. |
| 3. Genetics | ARG1 gene (6q23.2): 8 exons. About 100 variants. Missense variants are the most common. Autosomal recessive. Residual ARG1 activity correlates with clinical severity. |
| 4. General epidemiology | About 1 in 350,000–1,000,000, one of the rarest UCDs. Detected by elevated arginine on tandem MS/MS screening. Because severe encephalopathy rarely presents in the neonatal period, delayed diagnosis was common in the era before screening. |
| 5. Pathophysiology | ARG1 deficiency → arginine accumulation → excess production of guanidino compounds (guanidinoacetate, argininic acid) → neurotoxicity (GABA receptor inhibition, NMDA receptor action) → progressive spastic encephalopathy. Ammonia accumulation is milder than in other UCDs. |
| 6. Symptoms | Neonatal period: severe encephalopathy rare; failure to thrive, feeding difficulty. Childhood: progressive spastic paraplegia (spastic diplegia/paraplegia), seizures, cognitive impairment, failure to thrive, developmental delay. Adult late-onset form: spastic gait abnormality, cognitive decline. |
| 7. Signs | Markedly elevated plasma arginine (> 200 μmol/L, normal < 120 μmol/L). Mild to moderate elevation of blood ammonia. Mild elevation of urinary orotic acid. Lower-extremity spasticity, hyperactive deep tendon reflexes, positive Babinski sign. Seizures. Cognitive decline. |
| 8. Screening | Newborn tandem MS/MS: elevated blood arginine (> 200–300 μmol/L). Confirmation: plasma amino acids, erythrocyte ARG1 enzyme activity, ARG1 gene testing. |
| 9. Diagnosis | Markedly elevated plasma arginine, blood ammonia, urinary orotic acid, guanidino compound analysis, erythrocyte ARG1 enzyme activity, ARG1 gene NGS. |
| 10. Treatment | Low-arginine (low-protein) diet. Nitrogen scavengers (sodium benzoate/phenylbutyrate). Seizures: anticonvulsants. Spasticity: physical therapy, baclofen, orthoses. Hyperammonemic episodes: standard emergency management. Liver transplantation (curative treatment, normalizes arginine). Arginine-restricted diet + amino acid formula supplementation. |
| 11. Prognosis | Early treatment can suppress progression of spastic paraplegia. However, neurological damage that has already progressed is difficult to reverse. After liver transplantation, blood arginine normalizes, but complete recovery of neurological symptoms is limited. Early dietary management is key to the neurodevelopmental prognosis. |
| 12. Prevention | Early diagnosis by newborn screening. Early initiation of a low-arginine diet. Physical and occupational therapy to suppress progression of spasticity. Genetic counseling and family screening. Education on emergency management protocols. |
| 13. References | Häberle J et al. J Inherit Metab Dis. 2019, and 9 others |
Argininemia (hyperargininemia) was recognized as a clinical disease in 1969, when Terheggen et al. in Germany first described markedly elevated plasma arginine in patients with progressive spastic quadriplegia and intellectual disability. These patients did not show severe hyperammonemic encephalopathy in the neonatal period; instead, they showed a distinctive clinical course in which spastic motor impairment gradually appeared after childhood. This was the first observation suggesting that the neurotoxicity of arginine or its metabolites, rather than hyperammonemia, is the dominant pathophysiology.
Subsequently, taking advantage of the fact that the arginase enzyme can be measured in the liver and erythrocytes, measurement of erythrocyte ARG1 enzyme activity was established as a diagnostic method in the 1970s. This was used clinically as a convenient way to diagnose argininemia without a liver biopsy. The ARG1 gene is located on chromosome 6 (6q23.2) and was cloned in the late 1980s, initiating molecular biological research.
Since the 1990s, clinical experience has accumulated that a low-arginine diet (low-protein diet + amino acid formula) reduces arginine levels and suppresses the progression of symptoms. Adjunctive therapy with nitrogen scavengers (sodium benzoate, phenylbutyrate) was also introduced. As newborn screening by tandem mass spectrometry (MS/MS) spread in the 2000s, elevated blood arginine was established as a screening marker for argininemia, making early treatment before symptom onset possible. Clinical experience with liver transplantation as a curative treatment for argininemia has also accumulated, confirming that blood arginine normalizes after transplantation, but it has also become known that expectations for complete recovery of neurological symptoms are limited. Recently, research on AAV-based hepatocyte gene therapy and development of mRNA therapeutics targeting ARG1 deficiency are under way.
Argininemia is an autosomal recessive genetic disease caused by deficiency of arginase 1 (ARG1) due to pathogenic variants in the ARG1 gene (6q23.2). ARG1 is the last (5th) enzyme of the urea cycle and catalyzes the reaction that breaks down arginine into urea and ornithine. This reaction is the final step of urea synthesis and serves to close the urea cycle by regenerating ornithine.
When ARG1 is deficient, arginine cannot be broken down into urea and ornithine and accumulates in the blood, resulting in hyperargininemia. Ammonia accumulation also occurs, but it is characteristically milder than in deficiencies of the 4 upstream steps of the urea cycle (CPS1, OTC, ASS1, ASL). This is because the block is at the last step of the urea cycle, after the steps through citrulline and argininosuccinic acid have already proceeded, and only the last step through arginine is blocked. This is why, in ARG1 deficiency, progressive spastic motor impairment after childhood presents as the main symptom instead of severe neonatal hyperammonemia.
ARG1 is expressed mainly in the liver and erythrocytes. Because it is also expressed in erythrocytes, there is the clinical advantage that enzyme activity can be measured from a blood sample alone. In addition to urea synthesis, ARG1 function affects the regulation of intracellular arginine levels and the metabolism of related guanidino compounds. Neurotoxicity exerted by guanidino compounds (argininic acid, homoarginine, etc.) produced as byproducts when arginine accumulates excessively has been proposed as the mechanism of progressive neurological damage in argininemia.
The ARG1 gene is located on the long arm of chromosome 6 (6q23.2) and consists of 8 exons. The mature ARG1 protein is 322 amino acids, functions as a homotrimer, and requires manganese (Mn²⁺) ions as a cofactor. About 100 pathogenic variants have been reported to date, with missense variants accounting for the largest proportion. Complete loss-of-function variants (nonsense, frameshift, large deletions) are associated with severe phenotypes, and missense variants that leave residual enzyme activity are associated with a relatively mild course.
Genotype–phenotype correlations in argininemia have not been fully established, but in general, the lower the residual ARG1 enzyme activity, the higher the plasma arginine and the more severe the neurological symptoms tend to be. As recognition has strengthened that, in patients detected early by newborn screening, the toxicity of hyperargininemia itself (accumulation of guanidino compounds) is the main cause of neurological damage, the treatment principle has been established that early normalization of arginine levels (or maintenance of low arginine) is key to the neurodevelopmental prognosis.
Because inheritance is autosomal recessive, each parent of a patient is a heterozygous carrier without clinical symptoms. Each sibling has a 25% risk of being affected. After molecular genetic confirmation, family screening, prenatal diagnosis (CVS or amniocentesis), and preimplantation genetic testing (PGT) can be performed. ARG1 gene testing is used for confirmation together with elevated plasma arginine and reduced erythrocyte ARG1 activity.
Argininemia is one of the rarest urea cycle disorders (UCDs), with an estimated incidence of about 1 in 350,000–1,000,000 newborns. This is much rarer than OTC deficiency (about 1 in 14,000–17,000) and accounts for about 2–5% of all UCDs. The sex distribution is equal (autosomal recessive), and there are no reports that it is more common in specific ethnic groups or regions.
Because severe neonatal hyperammonemic encephalopathy is rare in argininemia, diagnosis was often considerably delayed before the introduction of tandem MS/MS newborn screening. Traditionally, it commonly first presented in childhood with progressive spastic paraplegia, developmental delay, and seizures, or was misdiagnosed as cerebral palsy or upper motor neuron disease. Cases not diagnosed until adulthood have also been reported. Since elevated blood arginine was included as a screening marker in tandem MS/MS newborn screening, early detection and initiation of treatment before symptom onset have become possible.
In Korea as well, arginine is included in the expanded newborn screening program, enabling early detection of newborns with argininemia. In Health Insurance Review & Assessment Service (HIRA) and rare disease registry data, argininemia is registered extremely rarely, and under code E72.2 it is eligible for Special Copayment Reduction V117. Although the incidence is low, the neurodevelopmental prognosis differs greatly depending on whether treatment is started early, so prompt confirmatory testing is important when newborn screening results are abnormal.
The pathophysiology of argininemia is understood along two axes: (1) neurotoxicity of guanidino compounds due to arginine accumulation and (2) mild hyperammonemia. Unlike other urea cycle disorders, the toxicity of arginine itself and its metabolites, rather than ammonia toxicity, is the main mechanism of neurological damage.
Neurotoxicity of guanidino compounds: when ARG1 is deficient, arginine cannot be converted to ornithine and accumulates in the blood. Excess arginine is converted through competitive or nonenzymatic reactions into several guanidino compounds: argininic acid (alpha-guanidinoglutaric acid), homoarginine, guanidinosuccinic acid, alpha-keto-delta-guanidinovaleric acid, and others. These compounds inhibit GABA-A receptors and activate NMDA receptors in neurons, causing excitotoxicity, which is proposed as the main mechanism of progressive spastic motor impairment and cognitive impairment. In particular, corticospinal tract neurons are vulnerable to guanidino compound toxicity, so upper motor neuron signs (spasticity, hyperreflexia, positive Babinski sign) characteristically appear.
Hyperammonemia (mild): in ARG1 deficiency, ammonia accumulation also occurs due to the block at the last step of the urea cycle, but it is much milder than in other UCDs (usually in the range of 100–200 μmol/L; the severe neonatal form is very rare). This is because the urea cycle proceeds through step 4, so the reactions converting ammonia to argininosuccinic acid and arginine still take place. Even mild hyperammonemia may partly contribute to long-term neurological damage.
Effects of ornithine deficiency: when ornithine is not produced from arginine, ornithine recycling in the urea cycle does not occur, reducing the efficiency of the urea cycle as a whole. This further worsens already inefficient urea synthesis.
Elevated urinary guanidinoacetic acid and orotic acid: excess arginine can increase production of guanidinoacetate as a byproduct, and because of ornithine deficiency, carbamoyl phosphate is diverted into the pyrimidine pathway, causing a mild elevation of orotic acid.
Unlike other urea cycle disorders, the clinical symptoms of argininemia show a distinctive course in which progressive neurological symptoms after childhood predominate instead of severe neonatal encephalopathy.
Neonatal period: severe hyperammonemic encephalopathy rarely presents. Neonatal symptoms, if any, are limited to feeding difficulty, failure to thrive, and mild jaundice, and altered consciousness or seizures are uncommon. Because of this, in the era before newborn screening, diagnosis was not made in the neonatal period in most cases.
Childhood (onset of spastic motor impairment): within a few months to a few years after birth, following normal development, lower-extremity spasticity gradually begins. Spastic paraplegia/diplegia is the most characteristic symptom of argininemia. The gait becomes scissors-like (scissors gait), the heels lift, and toe walking appears. As spasticity progresses, the ability to sit, stand, and walk declines. Seizures (generalized tonic-clonic, absence) are common in childhood, and intellectual disability and learning disabilities also progress. Failure to thrive is also present. Intermittent hyperammonemic episodes may occur but are much milder than in other UCDs.
Late-onset form (adulthood): in patients with mild residual activity, cases have been reported in which symptoms are not evident until adulthood and first present with progressive spastic gait abnormality and cognitive decline. In such cases, differentiation from multiple sclerosis and hereditary spastic paraplegia is needed.
Liver abnormalities: hepatomegaly may be present, and hepatic fibrosis has been reported in some patients. The mechanism of liver damage is presumed to be direct hepatotoxicity of arginine or guanidino compounds.
The main laboratory findings and physical signs of argininemia are as follows.
Markedly elevated plasma arginine: the key biochemical finding is a marked elevation of plasma arginine (> 200–500 μmol/L, 1,000 μmol/L or more in severe cases) compared with normal (40–120 μmol/L). This is detected as elevated arginine on tandem MS/MS newborn screening.
Blood ammonia: compared with other UCDs, it is mildly elevated (50–200 μmol/L) or sometimes within the normal range. Moderate elevation may occur during acute metabolic stress.
Neurological physical signs: lower-extremity spasticity: increased muscle tone, velocity-dependent resistance. Hyperactive deep tendon reflexes (DTR). Dorsiflexion of the great toe on plantar stimulation (positive Babinski sign). Gait abnormalities (scissors gait, toe walking). Seizures. Progressive upper motor neuron signs. Intellectual disability, delayed language development.
Urinary orotic acid: may be mildly elevated, but much lower than in other UCDs (OTC deficiency, ASS1 and ASL deficiencies).
Guanidino compound analysis: elevation of guanidino compounds (argininic acid, guanidinosuccinic acid, etc.) in urine or plasma is a finding associated with the neurotoxic mechanism of argininemia. They can be measured by specialized metabolic testing.
Erythrocyte ARG1 enzyme activity: reduced to less than 5% of controls.
Brain MRI: in some patients, cerebral cortical atrophy, abnormal signal in the corticospinal tracts (T2 hyperintensity), and cerebral white matter abnormalities are observed.
Argininemia is detected relatively effectively by elevated blood arginine on the tandem mass spectrometry (MS/MS) newborn screening panel.
Newborn tandem MS/MS screening: argininemia is suspected when blood arginine in a dried blood spot (DBS) is elevated to 200–300 μmol/L or higher. Blood arginine in normal newborns is usually < 120 μmol/L. Arginine elevation is relatively specific to argininemia, so screening specificity is higher than for other UCDs. However, because a normal blood arginine in the neonatal period cannot completely exclude argininemia, confirmatory testing is performed when there is clinical suspicion (spastic motor impairment, developmental delay).
Confirmatory testing: plasma amino acid chromatography (markedly elevated arginine, normal citrulline and argininosuccinic acid), blood ammonia, urinary organic acids (mildly elevated orotic acid), and urinary guanidino compound analysis. Measurement of erythrocyte ARG1 enzyme activity is useful for confirming the diagnosis. Pathogenic variants are identified by ARG1 gene panel NGS.
Arginine loading test: may be used to identify heterozygous carriers but is not used routinely in clinical practice.
The diagnosis of argininemia is made by characteristic biochemical findings and enzymatic and genetic confirmation.
Plasma amino acid chromatography: the key finding is a marked elevation of plasma arginine to 200–500 μmol/L or more (exceeding 1,000 μmol/L in severe cases). Plasma citrulline and argininosuccinic acid are normal, distinguishing it from other UCDs.
Blood ammonia: mild to moderate elevation during acute stress. Normal or mildly elevated in the chronic phase.
Urinary orotic acid: mild to moderate elevation. Excessive arginine excretion on urinary amino acids.
Guanidino compound analysis: argininic acid, guanidinosuccinic acid, and others are quantified in urine or plasma by specialized metabolic testing. Because these findings are associated with the neurotoxic mechanism, they are also used to evaluate treatment response.
Erythrocyte ARG1 enzyme activity: because ARG1 is expressed in erythrocytes, enzyme activity can be measured in whole blood or washed erythrocytes. A reduction to less than 5% of controls is diagnostic. There is the great advantage that diagnosis is possible with blood alone without a liver biopsy.
Molecular genetic confirmation: pathogenic variants are identified by ARG1 gene (6q23.2) panel NGS or Sanger sequencing. After variant confirmation, the results are used for family counseling and prenatal diagnosis.
Neurological testing: spasticity assessment (Modified Ashworth Scale), gait analysis, neurodevelopmental assessment, EEG (to check for epileptiform activity), brain MRI (corticospinal tract abnormalities, cortical atrophy).
The core goal of argininemia treatment is to lower plasma arginine levels to minimize guanidino compound toxicity. However, because arginine is not an essential amino acid, complete restriction is not possible, and dietary management that meets physiological requirements while preventing excess accumulation is needed.
Low-arginine diet (low-protein diet): restriction of natural protein intake reduces arginine intake. Amino acid formulas (essential amino acid mixtures with arginine removed or minimized) are supplemented to prevent essential amino acid deficiency. Early dietary management is the most important intervention for the neurodevelopmental prognosis. Maintaining a target plasma arginine level of 100–200 μmol/L or lower is recommended.
Nitrogen scavengers: sodium benzoate, sodium phenylbutyrate (NaPBA), or glycerol phenylbutyrate (GPB) is given orally to excrete nitrogen through urea-independent pathways, consequently reducing levels of arginine precursors (glutamine, glycine) and indirectly suppressing arginine production. They are added when dietary management alone does not adequately control plasma arginine.
Emergency management of hyperammonemic episodes: as with other UCDs, protein intake is stopped, high-calorie intravenous nutrition is provided, and intravenous nitrogen scavengers are given. In argininemia, additional arginine is not given (because arginine itself is the toxic substance).
Management of spasticity and seizures: to manage spastic motor impairment, physical therapy (muscle stretching, maintenance of motor function), occupational therapy, orthoses, and oral or intrathecal baclofen are used. Seizures are treated with standard anticonvulsants (valproic acid, levetiracetam, etc.).
Liver transplantation: liver transplantation is performed as a curative treatment for argininemia. After transplantation, hepatic ARG1 function normalizes, blood arginine decreases to normal levels, and protein restriction becomes unnecessary. However, complete recovery from spastic motor impairment and cognitive impairment that have already progressed before transplantation is limited even after transplantation, and stabilization or partial improvement of neurological symptoms after transplantation has been reported. Optimizing the timing of transplantation (before neurological damage worsens) is important.
The prognosis of argininemia depends greatly on the timing of treatment initiation and the level of plasma arginine control. Maintaining plasma arginine within the target range through early dietary management can suppress the progression of spasticity and slow cognitive decline. However, spastic motor impairment and neurological damage that have already progressed are difficult to reverse, so the timing of diagnosis and treatment initiation has a decisive effect on the prognosis.
Prognosis of patients treated early after newborn screening: there are cohort data showing that the onset and progression of spastic motor impairment and cognitive impairment are delayed in patients who started treatment before symptom onset through newborn screening. However, even with early treatment, some patients develop mild spasticity or borderline cognitive decline, so long-term neurodevelopmental outcomes vary greatly among individuals. Optimizing treatment (maintaining plasma arginine < 200 μmol/L) is most important for improving the neurodevelopmental prognosis.
Patients diagnosed late (diagnosed in childhood to adulthood): when spastic paraplegia, intellectual disability, and seizures have already progressed, complete recovery is difficult even after treatment. Suppressing further progression through dietary management and spasticity management is the realistic goal.
Prognosis after liver transplantation: after transplantation, blood arginine normalizes and production of guanidino compounds decreases. Cases have been reported in which spasticity and cognitive function stabilize or partly improve after transplantation. However, recovery from damage that has already occurred in the corticospinal tracts is limited. The transplant success rate is 95% or higher. Follow-up assessment of neurodevelopmental function after transplantation is needed.
Prevention in argininemia consists of early neonatal diagnosis, maintenance of target plasma arginine levels, and long-term management to prevent progressive neurological damage.
Early diagnosis by newborn screening: when blood arginine is elevated on tandem MS/MS newborn screening, immediate confirmatory testing and initiation of treatment are the most important preventive strategy. Starting a low-arginine diet early before symptom onset can delay or prevent the development of spastic motor impairment and cognitive impairment. Because severe neonatal encephalopathy is rare in argininemia and diagnosis may be delayed without screening, the role of newborn screening is especially important.
Plasma arginine monitoring: during treatment, plasma arginine is measured regularly (maintaining a target of < 200 μmol/L), and dietary management is intensified or the nitrogen scavenger dose adjusted as needed. Because excessive arginine restriction can cause failure to thrive, an individualized dietary plan is established under the guidance of a specialized metabolic dietitian.
Preventive management of spasticity and motor function: physical and occupational therapy are started early to prevent muscle shortening and joint contractures. Orthoses are used to maintain proper gait posture, and regular exercise (low-impact activities such as swimming and cycling) is recommended.
Genetic counseling and family screening: because inheritance is autosomal recessive, both parents of a patient are carriers. In subsequent pregnancies, the birth of an affected fetus can be prevented by prenatal diagnosis (CVS, amniocentesis) or preimplantation genetic testing (PGT). The 25% risk for siblings is discussed in counseling, and confirmatory testing is recommended.
Emergency management education: all patients and caregivers are educated on the emergency protocol of temporarily stopping protein intake and providing high-calorie intake during fever, infection, or loss of appetite. Carrying a medical alert card and sharing the contact information of the treating metabolic specialist are necessary.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230. DOI: 10.1002/jimd.12100. PMID: 30982989.
Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005;84(3):243-251. DOI: 10.1016/j.ymgme.2004.11.004. PMID: 15686953.
Deignan JL, Livesay JC, Yoo PK, et al. Guanidino compound levels and neurological damage in arginase-deficient mice. Mol Genet Metab. 2008;93(2):172-178. DOI: 10.1016/j.ymgme.2007.09.002. PMID: 17997120.
Sin YY, Baron G, Schulze A, Funk CD. Arginase-1 deficiency. J Mol Med (Berl). 2015;93(12):1287-1296. DOI: 10.1007/s00109-015-1354-3. PMID: 26458927.
Prasad AN, Breen JC, Ampola MG, Rosman NP. Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy. J Child Neurol. 1997;12(5):301-309. DOI: 10.1177/088307389701200504. PMID: 9220754.
Grobe H. Arginase deficiency and hyperargininaemia. Eur J Pediatr. 1979;130(1):29-38. PMID: 436540.
Terheggen HG, Lavinha F, Colombo JP, Van Sande M, Lowenthal A. Familial hyperargininaemia. J Genet Hum. 1972;20(1):69-84. PMID: 4636228.
Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders. Pediatr Clin North Am. 2018;65(2):231-246. DOI: 10.1016/j.pcl.2017.11.004. PMID: 29502910.
Rüegger CM, Lindner M, Ballhausen D, et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. J Inherit Metab Dis. 2014;37(5):741-752. DOI: 10.1007/s10545-014-9695-4. PMID: 24668256.
Iyer R, Jenkinson CP, Vockley JG, Kern RM, Grody WW, Cederbaum S. The human arginases and arginase deficiency. J Inherit Metab Dis. 1998;21 Suppl 1:86-100. DOI: 10.1023/a:1005313809037. PMID: 9686347.